How Are Authorized Representative Responsibilities Allocated for Overseas Registration of Laboratory Equipment?

Key Summary

The allocation of responsibilities for authorized representatives in overseas registration of laboratory equipment depends on the regulatory requirements of the target country, the product risk classification, and the eligibility of the applicant. Manufacturers must first determine whether the device falls within the target country's medical device regulatory scope, then select the registration pathway based on its risk class. Authorized representatives typically assume responsibilities such as communicating with regulatory authorities, submitting registration applications, receiving post-market vigilance reports, and assisting in adverse event handling. However, the fundamental responsibility for product technical files, quality systems, labeling and instructions for use, and clinical evaluations remains with the manufacturer.

Manufacturers need to prepare evidence such as quality management system certificates, technical documentation, risk management reports, and performance verification data, while assessing the reusability of existing documentation such as NMPA, CE, FDA, ISO 13485, and MDSAP. Common risks include authorized representatives exceeding their authority, loss of control over certificates, unclear responsibilities for changes and renewal, and poor coordination of post-market surveillance. It is recommended that manufacturers clarify the scope of authorization, cost allocation, and exit mechanisms at the project outset, and lock in both parties' responsibilities through a written agreement to avoid registration invalidation or compliance risks caused by representative failure.

For Chinese medical device manufacturers, a reliable approach is to first conduct a product classification and documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Registration in target markets typically affects technical files, authorized representative arrangements, importer coordination, label language, quality system evidence, and subsequent change maintenance. If the project is advanced merely by "submitting certain documents," it is easy to face correction or rework in model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends that manufacturers incorporate this issue into a unified GHWP member country and multi-country market access strategy, using one set of reusable core technical documentation to support localization in different markets rather than recreating documentation country by country.

Applicable Scenarios and Core Issues

Laboratory equipment refers to instruments, reagents, software, and their combinations used for medical testing, scientific research experiments, or clinical diagnostics, such as PCR analyzers, biochemical analyzers, immunoassay systems, centrifuges, and laboratory information systems. When such equipment is registered overseas, especially in GHWP member countries or markets in Southeast Asia, the Middle East, and Latin America, a local authorized representative is usually required instead of allowing the overseas manufacturer to submit the application directly.

The core issue with authorized representatives is not simply having a designated entity, but how responsibilities are allocated. Many manufacturers mistakenly believe that an authorized representative is merely responsible for submitting documents and receiving certificates. In practice, regulations often confer statutory duties on the authorized representative, such as liaison with regulatory authorities, receipt of post-market safety reports, and assistance with on-site inspections. If the boundary of responsibilities is unclear, manufacturers and representatives may shift blame during regulatory inquiries or adverse events, leading to suspension or revocation of the registration certificate.

When evaluating the applicable scenario, three questions must be answered first: Does the target country include the laboratory equipment under its medical device regulatory framework? Which risk class does the product belong to? Is the manufacturer able to act directly as the registration applicant? Taking GHWP member countries as an example, most countries require overseas manufacturers to appoint a local representative, but the specific authority and administrative role of the representative vary. Manufacturers cannot directly apply the CE or FDA model and must verify each country's requirements.

The core issue is not simply "who signs," but "who bears technical responsibility, who bears regulatory responsibility, and who bears post-market responsibility." Technical responsibility always rests with the manufacturer, including product design, performance verification, risk management, and clinical evaluation; regulatory responsibility is borne by the manufacturer or representative depending on national requirements; and post-market responsibility includes adverse event reporting, vigilance notices, and field safety corrective actions, often transmitted with the assistance of the authorized representative. Manufacturers should allocate responsibilities along these three dimensions rather than vaguely stating that "the representative is responsible for registration."

Registration Determination Logic

Step one: Determine whether the product falls within the target country's medical device regulatory scope. Not all countries regulate laboratory equipment as medical devices; for example, some purely research-use equipment may be exempt, or may be classified as accessories to IVD devices. Manufacturers should consult the target country's regulatory catalog or confirm with local regulatory authorities.

Step two: Determine the risk classification and registration pathway. Using the IMDRF or GHWP classification system as a reference, laboratory equipment is typically classified from low to high risk as Class A, B, C, or D, or under EU classification rules as Class I, IIa, IIb, or III. Different risk classifications correspond to different conformity assessment pathways; some may only require self-declaration, while others require notified body involvement or competent authority review.

Step three: Determine the applicant entity. Most countries allow overseas manufacturers to act as the registration applicant, but an authorized representative must be appointed. A few countries or specific pathways require a local entity as the applicant; in such cases, the authorized representative may also be the applicant and carries greater responsibility. Manufacturers need to determine in advance who holds the registration certificate and who has authority to change it, as this directly affects the boundary of the authorized representative's responsibilities.

Step four: Assess the reusability of existing documentation. If the manufacturer already holds NMPA registration, CE certification, FDA 510(k) or PMA, ISO 13485 certification, or MDSAP certification, these materials can serve as an important basis for technical documentation, but they cannot directly replace the target country's registration files. It is necessary to confirm whether the evidence meets local requirements and to undertake localization for language and standard differences.

Step five: Confirm post-market maintenance requirements. Authorized representatives are usually responsible for collecting and reporting adverse events, transmitting regulatory information, and cooperating with recalls or on-site inspections. Manufacturers should confirm whether the representative has the corresponding capability and resources, and specify information transmission timelines, reporting pathways, and record-keeping obligations.

Documentation and Evidence

Basic documentation that manufacturers need to prepare includes: product technical files (description, design, raw materials, working principles), performance verification and evaluation reports, risk management reports (compliant with ISO 14971), biocompatibility or electrical safety test reports (if applicable), software verification documents, stability data, clinical evaluation or clinical evidence, and samples of labels and instructions for use. These documents are generally submitted to regulatory authorities by the authorized representative.

Quality system evidence is an important basis for responsibility allocation. The target country may require the manufacturer to hold ISO 13485 certification or accept MDSAP audit reports. Even if not mandatory, manufacturers should provide quality system operation records when selecting an authorized representative, to prove that products continue to comply with regulatory requirements. Otherwise, if product issues arise from quality system deficiencies, representatives often refuse to bear joint risk.

The authorized representative's qualification documents also form part of the submission package. This includes the authorization agreement between the representative and the manufacturer, the representative's legal registration certificate in the target country, and a declaration that the representative assumes regulatory responsibilities. Some countries require that the scope of duties, validity period, and termination conditions be clearly specified in the authorization agreement; manufacturers should ensure the agreement content aligns with regulatory requirements.

For localization, product labels, instructions for use, and operation manuals must be translated into the official language of the target country and comply with local labeling requirements. Software interfaces and prompt messages may also need localization. If the laboratory equipment includes IVD functions, sample types, intended use, and performance indicators within the applicable scope must also be provided.

For multi-country registration, manufacturers should establish a documentation reuse matrix, clarifying which documents can be used across markets and which must be prepared separately. For example, general electrical safety reports can be reused, but country-specific local clinical laboratory evaluation reports must be generated specifically. This matrix also helps define what evidence the authorized representative needs to collect and supplement, avoiding redundant preparation.

Common Errors

• Mistaking the authorized representative for a registration agent: Assuming the representative only submits documents and bears no substantive responsibility. In reality, many countries grant representatives statutory duties such as receiving regulatory correspondence, submitting change applications, and assisting in adverse event reporting.
• Setting the authorization scope too broad or too narrow: An overly broad scope allows the representative to make unauthorized commitments on technical parameters or product design changes; an overly narrow scope prevents the representative from effectively performing duties, delaying the registration process.
• Ignoring control over the certificate: In some countries, the registration certificate holder is the authorized representative rather than the manufacturer. If the partnership breaks down, the manufacturer may lose the certificate or be forced to re-register.
• Unclear post-market surveillance responsibilities: When adverse events or regulatory inquiries occur, the manufacturer and representative may not know who drafts the report, who submits it, and within what deadline, creating compliance risks.
• Reusing old registration documentation without localization: Laboratory equipment often involves differences in voltage, plugs, language, and software versions. Submitting CE documentation directly may lead to correction requests or rejection.
• Failing to define change and renewal responsibilities: When product design changes, standards updates, or registration expiry renewals occur, if the agreement does not specify who initiates and follows up, the certificate may lapse.

Manufacturer Preparation Checklist

• Confirm the target country's regulatory scope and classification for the laboratory equipment, and record the basis for the determination in writing.
• Determine the registration pathway and applicant entity, and verify that the authorized representative has legal qualification and a good reputation in the target country.
• Sign a formal authorization agreement with the authorized representative, specifying the scope of duties, authority limits, fees, confidentiality clauses, and termination conditions.
• Establish a technical documentation list, including product description, performance verification, risk management, clinical evidence, labels, and instructions for use, with reuse and localization status noted.
• Compile quality system evidence, such as ISO 13485 certificates or MDSAP reports, and ensure they remain valid throughout the registration period.
• Develop a label and instruction localization plan to ensure language, measurement units, and warning statements meet target country requirements.
• Clarify the post-market adverse event reporting process, setting information transmission deadlines and responsible persons between the manufacturer and the representative.
• Plan change and renewal processes, and agree in the agreement who initiates change applications, who provides new evidence, and who pays costs.
• Establish a multi-country registration documentation reuse matrix, marking applicable markets by document type to reduce redundant preparation work.

AIMEILI Regulatory Perspective

The most common misjudgment among manufacturers is treating the authorized representative as an "administrative runner" and overlooking the representative's substantive role in regulatory law. For example, in some Southeast Asian and Middle Eastern countries, the authorized representative is not only responsible for communication but may also serve as the first recipient of post-market obligations. If the agreement does not clearly state this, manufacturers will discover at the time of an incident that the responsibility lies with them, but information must pass through the representative, causing critical delay.

At the project outset, the most important task is regulatory gap analysis, not signing a contract with a representative first. First determine whether the product can be registered, what evidence is needed, and what risk classification applies, then select an authorized representative. This provides an objective basis for discussing the scope of authorization; otherwise, manufacturers may be swayed by the representative and accept unreasonable responsibility clauses.

With respect to documentation, many technical reports from NMPA, CE, FDA, or ISO 13485 files can be reused, but labels, instructions for use, local language versions, and specific country clinical evaluation requirements must be generated anew. When reusing, be mindful of version differences; for example, a product classified under CE as IVDD may be managed under a higher risk class in the target country and require supplemental evidence.

Local representation, certificate control, and change and renewal must be negotiated as core contract clauses. Manufacturers should strive to retain ownership of the registration certificate. If regulations mandate that the representative hold the certificate, the agreement must include clear transfer and exit mechanisms. The initiation conditions, cost sharing, and timelines for changes and renewals must be detailed, not negotiated at the moment a change occurs.

For multi-country registrations, AIMEILI recommends that the manufacturer's headquarters uniformly manage the technical documentation archive, while authorized representatives are assigned only the local submission and communication functions. This reduces redundant preparation and correction risk and prevents different national representatives from unilaterally modifying documents. When regulatory differences arise, regulatory consultants should conduct a difference review, and then the local representative completes the localized submission.

Frequently Asked Questions

Can an authorized representative act for multiple companies simultaneously?

Most countries allow an authorized representative to act for multiple companies simultaneously, provided the representative has sufficient compliance capability and staffing. Manufacturers should review whether the representative handles competing products and require confidentiality measures.

What happens to the registration certificate if the collaboration with the authorized representative ends?

The outcome depends on the target country's regulations. If the certificate holder is the manufacturer, the authorized representative can be changed and the registration updated. If the holder is the original representative, it may be necessary to transfer the registration or reapply. Manufacturers should define the exit mechanism in the agreement.

May a manufacturer directly contact the regulatory authority without going through the authorized representative?

Most GHWP member countries require that all regulatory communication, especially registration submissions, changes, and adverse event reports, be conducted through the authorized representative. Direct contact by the manufacturer may be considered invalid; it is advisable to strictly route communication through the representative.